Hitachi Vantara To Acquire REAN Cloud
Deal Will Extend Hitachi Vantara's Cloud Portfolio and Managed Services Capabilities To Accelerate Digital Transformations Across Public, Private and Hybrid Cloud Environments
SANTA CLARA, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced its intent to acquire REAN Cloud LLC, a global cloud systems integrator, managed services provider and solutions developer of cloud-native applications across big data, machine learning and emerging internet of things (IoT) spaces.
Founded in 2013, REAN Cloud has quickly been recognized as a leading cloud systems integrator, earning the status of AWS Premier Consulting Partner and Microsoft Azure Silver Partner. REAN Cloud's deep hyperscale expertise and industry-leading infrastructure-as-code REAN Cloud Accelerator Platform enable highly automated, intelligent, scalable and secure cloud adoption and managed services. These services focus on delivering client business outcomes with significantly faster realization of business value. With 47Lining's capabilities (acquired by REAN Cloud last year), REAN Cloud also delivers customized solutions for IoT analytics, predictive analytics and machine learning, allowing customers to more quickly unlock new business opportunities.
This acquisition will reinforce Hitachi Vantara's ability to accelerate secure enterprise cloud adoption across multicloud environments and strengthen its ability to manage and operate traditional applications as well as emerging workloads in artificial intelligence and machine learning. Hitachi Vantara shares REAN Cloud's passion for creating leading-edge solutions and will leverage REAN Cloud's expertise to speed delivery of transformative digital solutions for its combined customers and partners.
"Our global customers across the Hitachi, Ltd., ecosystem are driving their own digital transformations to create competitive advantages in the marketplace," said Brian Householder, chief executive officer of Hitachi Vantara. "Modernized infrastructure running both on and off premises and intelligent data governance and analytics are the foundational pillars of digital transformations. REAN Cloud powerfully extends Hitachi Ltd.'s existing portfolio for customers and partners in these areas."
"Enterprises today want the ultimate flexibility in selecting the right environment for their varied workloads and development requirements. Moving and managing data and applications across environments requires careful orchestration through a unified cloud platform," said Bobby Soni, chief solutions and services officer of Hitachi Vantara. "Hitachi Vantara already offers trusted and reliable private cloud solutions for customers who want pay-as-you-go experiences without having to move their data off premises. With REAN Cloud, we will be able to extend our unified cloud offerings to public and hybrid clouds, and we will enable customers to accelerate their digital transformations by deploying analytics-centric solutions to drive business outcomes."
"When we first founded REAN Cloud, we understood the pivotal role that the cloud would play in transforming the way enterprises do business to reach their goals faster," said Sri Vasireddy, managing partner of REAN Cloud. "As cloud adoption continues its rapid growth worldwide, we are truly excited to join forces with Hitachi Vantara, which shares our focus on shaping the future of digital transformation with innovative solutions. Our team looks forward to evolving REAN Cloud's platform to accelerate customers' outcome-based offerings."
Once the acquisition closes, REAN Cloud's founders will continue to lead and grow the business as an integral part of Hitachi Vantara's Solutions and Services organization, led by Bobby Soni. REAN Cloud customers can expect continued high-quality services through REAN Cloud's existing workforce, enhanced by Hitachi Vantara's global delivery capabilities and leading digital solutions.
The transaction is expected to close later this year, subject to customary closing conditions and regulatory approvals. Financial terms of the deal are not being disclosed.
Citi acted as the exclusive financial advisor to Hitachi Vantara and William Blair and MVP acted as financial advisors to REAN Cloud.
For more information about Hitachi Vantara's intent to acquire REAN Cloud, read the blog post from Bobby Soni: https://www.hitachivantara.com/blog/a-clear-view-of-the-clouds/.
About REAN Cloud
REAN Cloud, a global cloud systems integrator and Managed Service Provider (MSP), is a Premier Consulting Partner in the Amazon Web Services (AWS) Partner Network (APN) and a Microsoft Azure Silver Partner. REAN Cloud offers managed and professional services and solutions for hyperscale integrated IaaS and PaaS providers and is one the few systems integrators capable of supporting the entire cloud services life cycle. Backed by extensive security DNA and deep compliance IP and expertise, REAN Cloud specializes in helping enterprise customers that operate in highly regulated environments - Financial Services, Healthcare/Life Sciences, Education and the Public Sector - to get the most from their cloud investment while enabling them to accelerate the value gained from the cloud once there. REAN Cloud's team has worked with global organizations, including the American Heart Association, Alexion Pharmaceuticals, Ditech Mortgage, Ellucian, Globus Genomics, Philips, PierianDx, SAP, Symantec, Teradata and Veritas. REAN Cloud solutions are bundled with advanced security features to help address clients' compliance needs.
About Hitachi Vantara
Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd., helps data-driven leaders find and use the value in their data to innovate intelligently and reach outcomes that matter for business and society. The company combines technology, intellectual property and industry knowledge to deliver data-managing solutions that help enterprises improve their customers' experiences, develop new revenue streams, and lower the costs of business. Only Hitachi Vantara elevates your innovation advantage by combining deep information technology (IT), operational technology (OT) and domain expertise. The company's experts work with organizations everywhere to drive data to meaningful outcomes. Visit us at www.hitachivantara.com.
About Hitachi, Ltd.
Hitachi, Ltd. (TSE:6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges, combining its operational technology, information technology, and products/systems. The company's consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.
HITACHI is a trademark or registered trademark of Hitachi, Ltd. All other trademarks, service marks, and company names are properties of their respective owners.
Company Contact Mary Ann Gallo Hitachi Vantara Mary.firstname.lastname@example.org 408-970-7932
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hitachi Vantara via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CEST | Pressemelding
Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi